Australia's Recce Pharmaceuticals, developing a New Class of Synthetic Anti-infectives, has announced the appointment of Dr Philip Sutton as Vice President of Translational Sciences.

Dr Sutton joined Recce’s Scientific Advisory Committee 21st August 2020 whilst leading the Mucosal Immunology Group at Murdoch Children’s Research Institute, investigating the potential of Recce’s anti-infectives across a suite of pre-clinical programs. He also served as the former Head of Immunology at CSL Limited in Melbourne, and has co-authored 99 peer-reviewed publications as well as Chief Editor of ‘Helicobacter pylori in the 21st Century’.

Joining the Company on a full-time basis, Dr Sutton will take a leading role advancing Recce’s compounds across a portfolio of infectious disease programs focussed on significant unmet medical needs.